NCT00144495View on ClinicalTrials.gov

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

PHASE3CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

November 30, 2004

Study Completion Date

May 31, 2005

Conditions
Chemotherapy Induced Anemia
Interventions
DRUG

recombinant human erythropoietin

3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks

DRUG

recombinant human erythropoietin

36000IU(s.c.)/week for 12 weeks

Sponsors
All Listed Sponsors
lead

Chugai Pharmaceutical

INDUSTRY